IDEAYA Biosciences: Executive Compensation & Equity Awards Detailed
Ticker: IDYA · Form: DEF 14A · Filed: Apr 30, 2025 · CIK: 1676725
| Field | Detail |
|---|---|
| Company | Ideaya Biosciences, Inc. (IDYA) |
| Form Type | DEF 14A |
| Filed Date | Apr 30, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, equity-awards, DEF-14A
TL;DR
IDEAYA's 2025 DEF 14A drops: exec comp & equity awards for 2024 detailed. Focus on PEO/Non-PEO fair values.
AI Summary
IDEAYA Biosciences, Inc. filed a DEF 14A on April 30, 2025, detailing executive compensation and equity awards for the fiscal year ending December 31, 2024. The filing includes information on the fair value of equity awards granted, outstanding and unvested awards, and changes in fair value for both executive (PEO) and non-executive (Non-PEO) members. Specific dates like 2024-01-01 and 2023-12-31 are referenced in relation to these awards.
Why It Matters
This filing provides crucial insights into how IDEAYA Biosciences compensates its top executives and employees, which can impact shareholder value and company performance.
Risk Assessment
Risk Level: medium — DEF 14A filings related to executive compensation can sometimes reveal information that impacts stock price, especially if compensation structures are unusual or if there are significant equity grants.
Key Players & Entities
- IDEAYA Biosciences, Inc. (company) — Filer of the DEF 14A
- 2024-01-01 (date) — Start of fiscal year for equity award reporting
- 2024-12-31 (date) — End of fiscal year for equity award reporting
- 2023-12-31 (date) — Previous fiscal year end for comparative equity award reporting
FAQ
What is the primary purpose of this DEF 14A filing for IDEAYA Biosciences, Inc.?
The primary purpose is to provide detailed information regarding the company's executive compensation, including equity awards granted, outstanding, and unvested awards for the fiscal year ending December 31, 2024.
What specific fiscal periods are covered by the equity award data in this filing?
The filing references equity award data for the fiscal year ending December 31, 2024, and includes comparative data from the fiscal year ending December 31, 2023.
What does 'PEO' and 'Non-PEO' refer to in the context of this filing?
'PEO' likely refers to the Principal Executive Officer (CEO) and other top executives, while 'Non-PEO' refers to other executive officers and potentially other employees receiving equity awards.
What type of compensation details are being disclosed?
The filing discloses details about equity awards, including their fair value at grant, changes in fair value, and outstanding/unvested award values.
When was this DEF 14A filing submitted to the SEC?
This DEF 14A filing was submitted to the SEC on April 30, 2025.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 30, 2025 regarding IDEAYA Biosciences, Inc. (IDYA).